Mitomycin Accord (Mitomycin)

Mitomycin is a bioreductive alkylating agent. Inside hypoxic tumour cells it is reduced to a reactive intermediate that forms covalent cross‑links between DNA strands, especially at guanine residues. This cross‑linking blocks DNA replication and transcription, leading to apoptosis of rapidly dividing cancer cells.

The dose of Mitomycin Accord is individualized by the treating physician based on the specific cancer type, treatment regimen, patient weight, renal function and prior therapy. Dosing schedules are defined in clinical protocols and must be prescribed by a qualified oncologist.

Mitomycin is classified as potentially harmful to the fetus and is generally contraindicated during pregnancy unless the expected therapeutic benefit outweighs the risk. It is also excreted in breast milk, so breastfeeding is not recommended while receiving treatment. Consultation with a specialist is essential for any pregnant or nursing patient.

To request Mitomycin Accord, visit the product page on gnhindia.com, enter the required quantity and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Mitomycin differs from many conventional chemotherapeutics because it requires enzymatic activation in low‑oxygen environments, giving it selective activity in hypoxic tumour regions. Compared with other alkylating agents, it has a distinct DNA cross‑linking pattern and is often used when tumours are resistant to agents such as cyclophosphamide or cisplatin.

Mitomycin Accord should be stored refrigerated at 2‑8 °C, protected from light, and never frozen or shaken. The product must be kept in its original packaging until use to maintain sterility. During preparation, follow aseptic techniques and discard any solution that appears discolored or particulate.

The medication is supplied as a sterile solution for intravenous infusion or intravesical instillation. Intravenous dosing is given over a defined period, usually as a short infusion, while intravesical therapy involves filling the bladder with the solution and retaining it for a prescribed dwell time under clinical supervision.

Serious adverse events include severe myelosuppression leading to infection or bleeding, hemorrhagic cystitis, pulmonary toxicity such as interstitial pneumonitis or fibrosis, and life‑threatening infections. Patients should be monitored closely for signs of infection, respiratory difficulty, hematuria or unexplained fatigue, and treatment should be adjusted promptly if these occur.

Mitomycin Accord is contraindicated in patients with severe bone‑marrow suppression, uncontrolled infections, known hypersensitivity to mitomycin or related compounds, and in pregnant women unless the therapeutic benefit justifies the risk. Caution is also advised for individuals with significant renal impairment or those receiving concurrent nephrotoxic therapies.